Anti-TNF Therapy and the Risk of Cancer and Infection in Pakistani Rheumatoid Arthritis Patients: A Case-Control Study
DOI:
https://doi.org/10.53350/pjmhs02025191.6Keywords:
Rheumatoid arthritis, anti-TNF therapy, cancer risk, infection risk, biomarkers, inflammation, immunomodulation, biologics.Abstract
Background: Rheumatoid arthritis functions as a persistent autoimmune condition which creates major consequences for patient lifestyle quality. TNF inhibitor medications (anti-TNF therapy) have transformed RA treatment by lowering inflammation yet medical practitioners still worry about their ability to enhance infection and cancer risks.
Aim: To evaluate the risk of infection and malignancy in rheumatoid arthritis (RA) patients undergoing anti-TNF therapy, comparing them with those receiving conventional treatment.
Methods: A total of 500 RA patients, aged 20-50 years, were recruited from multiple tertiary care hospitals in Lahore, Pakistan. The cohort was divided into two groups: Group A (Non-Biologic, n=250) and Group B (Biologic, n=250). Demographic data, lifestyle factors, disease duration, and biomarkers including CRP, IL-6, TNF-α, PCT, serum ferritin, immunoglobulin levels, RF, and ACPA were measured. Statistical analyses, including descriptive statistics, t-tests, and logistic regression, were performed. Kaplan-Meier survival analysis was conducted to assess long-term patient outcomes.
Results: The Biologic Group showed significantly reduced levels of inflammatory markers (CRP, IL-6, TNF-α) compared to the Non-Biologic Group, indicating better disease control. Elevated immunoglobulin levels (IgG, IgA) in the Biologic Group suggested immune modulation. While infection rates were comparable between both groups, the Biologic Group showed a lower risk of severe disease progression. The Kaplan-Meier survival analysis indicated a statistically significant survival advantage for the Biologic Group (χ² = 5.67, p = 0.017).
Conclusion: Anti-TNF therapy effectively reduces inflammation and improves clinical outcomes in RA patients without introducing significant new health risks. However, regular monitoring for infections and malignancies, especially non-melanoma skin cancers, is essential to optimize long-term safety. The study highlights the therapeutic benefit of biologics while emphasizing the need for tailored patient care and continuous surveillance.
References
Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, et al. Cancer risk in patients with rheumatoid arthritis treated with anti–tumor necrosis factor α therapies: Does the risk change with the time since start of treatment? Arthritis & Rheumatism. 2009;60(11):3180-9.doi: https://doi.org/10.1002/art.24941
Shumaila, Yousuf F, Noor AM, Sultan D, Imran U, Abdullah, et al. Long-Term Safety and Efficacy of Janus kinase (JAK) Inhibitors in the Treatment of Rheumatoid Arthritis: Disease Control in Rheumatoid Arthritis with JAK Inhibitors. DEVELOPMENTAL MEDICO-LIFE-SCIENCES. 2024;1(4):71-8.doi: 10.69750/dmls.01.04.039
Jacobsson LT, Turesson C, Nilsson JA, Petersson IF, Lindqvist E, Saxne T, et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66(5):670-5.doi: 10.1136/ard.2006.062497
Emery P, Furst DE, Kirchner P, Melega S, Lacey S, Lehane PB. Risk of Malignancies in Patients with Rheumatoid Arthritis Treated with Rituximab: Analyses of Global Postmarketing Safety Data and Long-Term Clinical Trial Data. Rheumatol Ther. 2020;7(1):121-31.doi: 10.1007/s40744-019-00183-6
Chen Y, Friedman M, Liu G, Deodhar A, Chu C-Q. Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders? Cytokine. 2018;101:78-88.doi: https://doi.org/10.1016/j.cyto.2016.09.013
Carmona L, Abasolo L, Descalzo MA, Pérez-Zafrilla B, Sellas A, de Abajo F, et al. Cancer in Patients with Rheumatic Diseases Exposed to TNF Antagonists. Seminars in Arthritis and Rheumatism. 2011;41(1):71-80.doi: https://doi.org/10.1016/j.semarthrit.2010.08.005
Saeed U, Ali M, Mahmood F, Saeed S, Mudassar S, Ahmed J. Lipid Peroxidation and Detection of Pro-Inflammatory Variables in Rheumatoid Arthritis- A Comprehensive Analysis of Malondialdehyde and Isoprostanes in Synovial Fluids and SERA: Assessing Lipid Peroxidation and Inflammation in Rheumatoid Arthritis. DEVELOPMENTAL MEDICO-LIFE-SCIENCES. 2024;1(2):1-7.doi: 10.69750/dmls.01.02.019
Riek M, Scherer A, Möller B, Ciurea A, von Mühlenen I, Gabay C, et al. Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care. Scientific Reports. 2023;13(1):17776.doi: 10.1038/s41598-023-44841-w
Delcoigne B, Kopp TI, Arkema EV, Hellgren K, Provan SA, Relas H, et al. Exposure to specific tumour necrosis factor inhibitors and risk of demyelinating and inflammatory neuropathy in cohorts of patients with inflammatory arthritis: a collaborative observational study across five Nordic rheumatology registers. RMD Open. 2023;9(1):e002924.doi: 10.1136/rmdopen-2022-002924
Balanescu AR, Citera G, Pascual-Ramos V, Bhatt DL, Connell CA, Gold D, et al. Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2022;81(11):1491-503.doi: 10.1136/ard-2022-222405
Jiang Z, Zou Y, Li G, Zhao S, Zhang W. Comparisons of infection events associated with tumor necrosis factor inhibitors in patients with inflammatory arthritis: A systematic review and network meta-analysis. Frontiers in Pharmacology. 2024;15.doi: 10.3389/fphar.2024.1376262
Lan J-L, Tseng C-H, Chen J-H, Cheng C-F, Liang W-M, Tsay GJ. Reduced risk of all-cancer and solid cancer in Taiwanese patients with rheumatoid arthritis treated with etanercept, a TNF-α inhibitor. Medicine. 2017;96(7):e6055.doi: 10.1097/md.0000000000006055
Chen J-W, Zhang W-S, Lin C-S, Xu Q. Case report: JAKi and TNFi dual therapy is a potential treatment strategy for difficult-to-treat rheumatoid arthritis. Frontiers in Immunology. 2022;13.doi: 10.3389/fimmu.2022.1074329
Tanaka Y, Takeuchi T, Harigai M, Yamanaka H, Nakano T, Akagi K, et al. Efficacy and safety of sirukumab in Japanese patients with active rheumatoid arthritis who were refractory or intolerant to anti-tumor necrosis factor therapy: Subgroup analysis of a randomized, double-blind, multicenter, phase 3 study (SIRROUND-T). Modern Rheumatology. 2019;29(2):306-13.doi: 10.1080/14397595.2018.1452345
Rosman Z, Shoenfeld Y, Zandman-Goddard G. Biologic therapy for autoimmune diseases: an update. BMC Medicine. 2013;11(1):88.doi: 10.1186/1741-7015-11-88
Pundole X, Zamora NV, Siddhanamatha H, Lin H, Tayar J, Leung CH, et al. Overall survival in patients with rheumatoid arthritis and solid malignancies receiving biologic disease-modifying antirheumatic therapy. Clinical Rheumatology. 2020;39(10):2943-50.doi: 10.1007/s10067-020-05318-7
Calvo-Garcia A, Ramírez Herráiz E, Llorente Cubas IM, Varas De Dios B, Benedí González J, Morell Baladrón A, et al. The Real-World Effectiveness, Persistence, Adherence, and Safety of Janus Kinase Inhibitor Baricitinib in Rheumatoid Arthritis: A Long-Term Study. Journal of Clinical Medicine [Internet]. 2024; 13(9).doi: 10.3390/jcm13092517
Chanchlani N, Lin S, Bewshea C, Hamilton B, Thomas A, Smith R, et al. Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study. The Lancet Gastroenterology & Hepatology. 2024;9(6):521-38.doi: 10.1016/S2468-1253(24)00044-X
Findeisen KE, Sewell J, Ostor AJK. Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician. Biologics: Targets and Therapy. 2021;15(null):343-52.doi: 10.2147/BTT.S252575
Park D-J, Choi S-E, Kang J-H, Shin K, Sung Y-K, Lee S-S. Comparison of the efficacy and risk of discontinuation between non-TNF-targeted treatment and a second TNF inhibitor in patients with rheumatoid arthritis after first TNF inhibitor failure. Therapeutic Advances in Musculoskeletal Disease. 2022;14:1759720X221091450.doi: 10.1177/1759720x221091450
Lambert JLW, De Schepper S, Speeckaert R. Cutaneous Manifestations in Biological-Treated Inflammatory Bowel Disease Patients: A Narrative Review. Journal of Clinical Medicine [Internet]. 2021; 10(5).doi: 10.3390/jcm10051040
Nguyen ED, Gabel CK, Kroshinsky D. Assessing the incidence of skin and soft tissue infection in patients on biologics. Journal of the American Academy of Dermatology. 2021;85(3):604-10.doi: 10.1016/j.jaad.2020.03.128
Emery P, Furst DE, Kirchner P, Melega S, Lacey S, Lehane PB. Risk of Malignancies in Patients with Rheumatoid Arthritis Treated with Rituximab: Analyses of Global Postmarketing Safety Data and Long-Term Clinical Trial Data. Rheumatology and Therapy. 2020;7(1):121-31.doi: 10.1007/s40744-019-00183-6
Choi SR, Shin A, Ha Y-J, Lee YJ, Lee EB, Kang EH. Comparative risk of infections between JAK inhibitors versus TNF inhibitors among patients with rheumatoid arthritis: a cohort study. Arthritis Research & Therapy. 2023;25(1):129.doi: 10.1186/s13075-023-03111-w
Downloads
How to Cite
Issue
Section
License
Copyright (c) 2025 MUHAMMAD NAUMAN SHAHID, MIAN SARMAD FAYAZ, AREESHA ANAM, UMER FAROOQ, HAMZA SALEEM, MUHAMMAD SAMI UL HASSAN, MISHAAL RAZZAQ, ARSLAN SHUJA
This work is licensed under a Creative Commons Attribution 4.0 International License.
